News

EdiGene Announces Approval in China of its IND Application for CRISPR/Cas 9 Gene Editing Therapy ET-01 in β-thalassaemia

EdiGene Announces Approval in China of its IND Application for CRISPR/Cas 9 Gene Editing Therapy ET-01 in β-thalassaemia

The Center for Drug Evaluation (CDE) of China‘s National Medical Products Administration (NMPA) has recently approved EdiGene’s application for ET-01, an investigational CRISPR-Cas9 gene editing therapy for patients with transfusion dependent β-thalassaemia. This marks the first…
Just Updated: TIF’s Vaccinations & Therapeutic Drugs for COVID-19 Guide

Just Updated: TIF’s Vaccinations & Therapeutic Drugs for COVID-19 Guide

Everything you need to know about the different COVID-19 vaccines, both already available and developing, in one place! Discover our newly updated Guide ”Vaccinations & Therapeutic Drugs for COVID-19”, containing…
Iranian Blood Transfusion Organization Newsletter – December 2020

Iranian Blood Transfusion Organization Newsletter – December 2020

The Iranian Blood Transfusion Organization (IBTO) and its most recent activities are featured on TIF’S website.
Blood Under The Microscope Of The European Commission: An Article by TIF’s Executive Director

Blood Under The Microscope Of The European Commission: An Article by TIF’s Executive Director

by Dr Androulla Eleftheriou The European Commission published in October 2019 the Evaluation Report of the European legal framework for quality standards and blood, tissues and cells. This framework is…
THALIA App: The Skilled Digital Assistant of People with Thalassaemia and Sickle Cell Disease

THALIA App: The Skilled Digital Assistant of People with Thalassaemia and Sickle Cell Disease

Committed to continuing efforts to develop useful tools for individuals with thalassaemia and haemoglobin disorders worldwide, TIF introduces a novel mobile health application for patients with thalassaemia and sickle cell…
COVID-19 Vaccines and Haemoglobin Disorders: The Latest Position Statement of the Thalassaemia International Federation

COVID-19 Vaccines and Haemoglobin Disorders: The Latest Position Statement of the Thalassaemia International Federation

In view of the plans made by national health authorities in every country across the world for the widespread vaccination of individuals against the SARS-CoV-2 virus, the Thalassaemia International Federation…
TIF & UNITED Onlus To Co-Host The 1st PanItalian Associations Meeting On New Therapies For Haemoglobinopathies

TIF & UNITED Onlus To Co-Host The 1st PanItalian Associations Meeting On New Therapies For Haemoglobinopathies

In light of the tremendous scientific developments in the field of thalassemia and sickle cell disease (SCD) with new drugs and treatments that promise to revolutionize the management of these…
TIF Guidelines For The Management Of Transfusion Dependent Thalassaemia 4th Edition Arriving Soon!

TIF Guidelines For The Management Of Transfusion Dependent Thalassaemia 4th Edition Arriving Soon!

TIF, its Board of Directors, and International Scientific Advisory Board proudly announce that the 4th edition of the Federation’s most acclaimed and sought-after publication, TIF Guidelines For The Management of…
TIF European Thalassaemia & Sickle Cell Disease Symposium To Take Place On 11-13 December 2020

TIF European Thalassaemia & Sickle Cell Disease Symposium To Take Place On 11-13 December 2020

TIF is proudly organising the European Thalassaemia & Sickle Cell Disease Symposium, a joint patients’ and healthcare professionals’ three-day educational event which will take place online on 11 – 13 December…
Back to top button